A trial looking at panobinostat for advanced cancer to see how your kidneys affect what happens to the drug in your body

Cancer type:

All cancer types




Phase 1

This trial aimed find out more about how the body absorbs and gets rid of a drug called panobinostat. It was for people with a solid tumour that had spread (advanced cancer). A solid tumour Open a glossary item is any type of cancer apart from leukaemia Open a glossary item or lymphoma Open a glossary item.

More about this trial

One of the important jobs that your kidneys do is to get rid of drugs from the body. But if you have advanced cancer Open a glossary item, your kidneys may not be working very well. Doctors can measure how well your kidneys are working (your kidney function) by doing blood and urine tests.

Panobinostat is a drug that blocks certain proteins (enzymes) Open a glossary item. Cells need these enzymes to grow and divide. Blocking them may stop cancer growing.

Studying what happens to a drug in the body is called pharmacokinetics Open a glossary item.This includes looking at how long the drug stays in the body and how your body gets rid of it.

The aims of this trial were to

  • Find out more about what happens to panobinostat in people with different levels of kidney function
  • Learn more about the side effects


Summary of results

The study team found that it was safe to give panobinostat to people with kidney problems and the side effects were mild.

37 people took part in this study. Of those, 26 had kidney problems that ranged from mild to severe.

The researchers took blood samples from everyone before the first dose of panobinostat then every few hours after having the drug and a final sample after 96 hours. They collected regular urine samples up to 24 hours after the 1st dose. They also took more blood samples from the people who continued having panobinostat to check the levels of the drug in their blood.

The researchers looked at the blood and urine samples. They found that the level of panobinostat in the body wasn’t higher in the people who had kidney problems and wasn’t any higher in the people with severe kidney problems.

The main side effects of panobinostat were

  • Feeling or being sick
  • Tiredness (fatigue)
  • Loss of appetite
  • Bleeding problems
  • Breathing problems

These didn’t seem to be much worse in people who had kidney problems.

The trial team concluded that it is safe to give panobinostat to people with mild to severe kidney problems without having to change the starting dose of the drug for this group of people.

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Syed Hussain

Supported by


Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10693

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Over 60,000 cancer patients enrolled on clinical trials in the UK last year.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page